Non-alcoholic fatty liver disease – A global public health perspective

Marcellin, 2018, Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening, Liver Int, 38, 2, 10.1111/liv.13682 Mokdad, 2014, Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis, BMC Med, 12, 145, 10.1186/s12916-014-0145-y Stepanova, 2017, Direct and indirect economic burden of chronic liver disease in the United States, Clin Gastroenterol Hepatol, 15, 10.1016/j.cgh.2016.07.020 Kim, 2018, Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016, Gastroenterology, 10.1053/j.gastro.2018.07.008 Younossi, 2018, Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Hepatology, 10.1002/hep.30251 WHO Expert Consultation, 2004, Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies, Lancet, 363 Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO 11 October 2017 News Release LONDON- http://www.who.int/news-room/detail/11-10-2017-tenfold-increase-in-childhood-and-adolescent-obesity-in-four-decades-new-study-by-imperial-college-london-and-who. World Obesity Facts. Obtained from the world wide web at: https://renewbariatrics.com/obesity-rank-by-countries/. Type 2 Diabetes Mellitus-International Diabetes Federation. IDF diabetes atlas. 8th ed. 2017 obtained from the world wide web at http://www.diabetesatlas.org/. WHO Diabetes Fact Sheets. Obtained from the world wide web at: http://www.who.int/news-room/fact-sheets/detail/diabetes. Centers for Disease Control. Rates of new diagnosed cases of type 1 and type 2 diabetes on the rise among children, teens. Obtained from the world wide web at: https://www.cdc.gov/media/releases/2017/p0412-diabtes-rates.html. Fan, 2017, New trends on obesity and NAFLD in Asia, J Hepatol, 67, 862, 10.1016/j.jhep.2017.06.003 World Health Organization (WHO). Obesity and overweight. Obtained from the world wide web at: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. World Health Assembly. Action plan to reduce global obesity. Obtained from the world wide web at: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Camhi, 2011, The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences, Obesity, 19, 402, 10.1038/oby.2010.248 Mongraw-Chaffin, 2015, The sex and race specific relationship between anthropometry and body fat composition determined from computed tomography: evidence from the multi-ethnic study of atherosclerosis, PLoS One, 10, 10.1371/journal.pone.0139559 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Sayiner, 2016, Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the united states and the rest of the world, Clin Liver Dis, 20, 205, 10.1016/j.cld.2015.10.001 Cotrim, 2016, Nonalcoholic Fatty Liver Disease Brazilian Society of Hepatology consensus, Arq Gastroenterol, 53, 118, 10.1590/S0004-28032016000200013 López-Velázquez, 2014, The prevalence of nonalcoholic fatty liver disease in the Americas, Ann Hepatol, 13, 166, 10.1016/S1665-2681(19)30879-8 Andrade, 2016, Non-alcoholic fatty liver disease (NAFLD) in different populations: a clinical and epidemiological study – sample of São José do Rio Preto, Rev Assoc Med Bras (1992), 62, 218, 10.1590/1806-9282.62.03.218 Fan, 2013, Epidemiology of alcoholic and nonalcoholic fatty liver disease in China, J Gastroenterol Hepatol, 28, 11, 10.1111/jgh.12036 Eguchi, 2012, Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study, J Gastroenterol, 47, 586, 10.1007/s00535-012-0533-z Zois, 2010, Steatosis and steatohepatitis in postmortem material from Northwestern Greece, World J Gastroenterol, 16, 3944, 10.3748/wjg.v16.i31.3944 Caballería, 2010, Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain, Eur J Gastroenterol Hepatol, 22, 24, 10.1097/MEG.0b013e32832fcdf0 Das, 2010, Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease, Hepatology, 51, 1593, 10.1002/hep.23567 Dassanayake, 2009, Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population, J Gastroenterol Hepatol, 24, 1284, 10.1111/j.1440-1746.2009.05831.x 2012 National Health Survey: First Results, 2014–15. http://www.abs.gov.au/ausstats/[email protected]/mf/4364.0.55.001. Coppell, 2015, Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey, Obes Sci Pract, 1, 67, 10.1002/osp4.13 Frith, 2009, Non-alcoholic fatty liver disease in older people, Gerontology, 55, 607, 10.1159/000235677 Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527 Li, 2009, Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China, Hepatobiliary Pancreat Dis Int, 8, 377 Summart, 2017, Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study, F1000Research, 6, 1630, 10.12688/f1000research.12417.1 Messiah, 2016, Ethnic and gender differences in the prevalence of nonalcoholic steatohepatitis among bariatric surgery patients, Bariatr Surg Pract Patient Care, 11 Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283 Kalia, 2016, The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities, Clin Liver Dis, 20, 215, 10.1016/j.cld.2015.10.005 Walker, 2012, High rates of fructose malabsorption are associated with reduced liver fat in obese African Americans, J Am Coll Nutr, 31, 369, 10.1080/07315724.2012.10720445 Kotronen, 2009, A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans, Diabetologia, 52, 1056, 10.1007/s00125-009-1285-z Sharma, 2015, The riddle of nonalcoholic fatty liver disease: progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis, J Clin Exp Hepatol, 5, 147, 10.1016/j.jceh.2015.02.002 Dongiovanni, 2013, Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment, Curr Pharm Des, 19, 5219, 10.2174/13816128113199990381 Estes, 2018, Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 Younossi, 2012, Nonalcoholic fatty liver disease in lean individuals in the United States, Medicine (Baltimore), 91, 319, 10.1097/MD.0b013e3182779d49 Kumar, 2017, Non-alcoholic fatty liver disease in lean subjects: characteristics and implications, J Clin Transl Hepatol, 5, 216 Younossi, 2013, In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not, Metabolism., 62, 352, 10.1016/j.metabol.2012.08.005 Feldman, 2017, Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients, J Hepatol, 66, S149, 10.1016/S0168-8278(17)30570-6 Otgonsuren, 2013, Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease, Dig Dis Sci, 58, 1132, 10.1007/s10620-012-2446-3 Dela Cruz, 2014, 379 characteristics and longterm prognosis of lean patients with nonalcoholic fatty liver disease, Gastroenterology, 146, S909, 10.1016/S0016-5085(14)63307-2 Wei, 2015, Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy, Am J Gastroenterol, 110, 1306, 10.1038/ajg.2015.235 Hu, 2012, Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units, BMC Gastroenterol, 12, 123, 10.1186/1471-230X-12-123 Chan, 2018, Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative, Aliment Pharmacol Ther, 47, 816, 10.1111/apt.14506 Fazel, 2016, Epidemiology and natural history of non-alcoholic fatty liver disease, Metabolism, 65, 1017, 10.1016/j.metabol.2016.01.012 McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034 Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 10.1016/j.cgh.2014.04.014 Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016/j.jhep.2013.04.027 Han, 2018, Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis, Clin Gastroenterol Hepatol Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 2016, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004 Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, 10.1371/journal.pmed.1001680 Golabi, 2018, Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD), Medicine (Baltimore), 97, 10.1097/MD.0000000000010214 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Mittal, 2016, Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 14, 10.1016/j.cgh.2015.07.019 Seyda Seydel, 2016, Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries, Ann Hepatol, 15, 662 Baffy, 2012, Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace, J Hepatol, 56, 1384, 10.1016/j.jhep.2011.10.027 Stine, 2018, Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases, Aliment Pharmacol Ther, 10.1111/apt.14937 Bertuccio, 2017, Global trends and predictions in hepatocellular carcinoma mortality, J Hepatol, 67, 302, 10.1016/j.jhep.2017.03.011 Stepanova, 2013, Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD), Dig Dis Sci, 58, 3017, 10.1007/s10620-013-2743-5 Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 10.1053/j.gastro.2015.04.043 Younossi, 2017, Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease, Hepatol Commun, 1, 421, 10.1002/hep4.1054 Spahillari, 2016, The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study, Nutr Metab Cardiovasc Dis, 26, 1039, 10.1016/j.numecd.2016.06.011 Stepanova, 2012, Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population, CGH, 10, 646 Saponaro, 2015, Curr Diab Rep, 15, 34, 10.1007/s11892-015-0607-4 Gaggini, 2013, Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease, Nutrients, 5, 1544, 10.3390/nu5051544 Bugianesi, 2012, Hepatic and cardiac steatosis: are they coupled?, Heart Fail Clin, 8, 663, 10.1016/j.hfc.2012.06.010 Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 10.1053/j.gastro.2018.04.034 Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123 Kim, 2018, Changing trends in etiology- and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States, Hepatology Younossi, 2018, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation, Liver Transpl, 24, 166, 10.1002/lt.25003 Cholankeril, 2017, Liver transplantation for nonalcoholic steatohepatitis in the us: temporal trends and outcomes, Dig Dis Sci, 62, 2915, 10.1007/s10620-017-4684-x Younossi, 2018, Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol Tavakoli, 2017, Cirrhosis patients with nonalcoholic steatohepatitis are significantly less likely to receive surveillance for hepatocellular carcinoma, Dig Dis Sci, 62, 2174, 10.1007/s10620-017-4595-x Young, 2016, Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma, Liver Transpl, 22, 1356, 10.1002/lt.24507 Younossi, 2011, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, 10.1016/j.cgh.2011.03.020 Kim, 2014, Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years, Cancer, 120, 3058, 10.1002/cncr.28843 Desai, 2018, Geographic variability in liver disease-related mortality rates in the United States, Am J Med, 131, 728, 10.1016/j.amjmed.2018.01.047 Pimpin, 2018, Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies, J Hepatol, 69, 718, 10.1016/j.jhep.2018.05.011 Wiegand, 2013, The etiology, diagnosis and prevention of liver cirrhosis: Part 1 of a series on liver cirrhosis, Dtsch Arztebl Int, 110, 85 Mukherjee, 2017, Etiology and mode of presentation of chronic liver diseases in India: a multi centric study. Ray R, ed., PLoS One, 12, 10.1371/journal.pone.0187033 Wong, 2018, The changing epidemiology of liver diseases in the Asia-Pacific region, Nat Rev Gastroenterol Hepatol Younossi, 2018, Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Clin Liver Dis, 22, 1, 10.1016/j.cld.2017.08.001 Stepanova, 2017, Direct and indirect economic burden of chronic liver disease in the United States, Clin Gastroenterol Hepatol, 15, 10.1016/j.cgh.2016.07.020 Allen, 2018, Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database, Hepatology, 10.1002/hep.30094 Younossi, 2015, Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease, J Clin Gastroenterol, 49, 222, 10.1097/MCG.0000000000000071 Sayiner, 2017, Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis, J Clin Gastroenterol, 51, 254, 10.1097/MCG.0000000000000567 Ofosu, 2018, Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions, Ann Gastroenterol, 31, 288 Younossi, 2018, Burden of illness and economic model for patients with non-alcoholic steatohepatitis (NASH) in the United States, Hepatology Patient Reported Outcomes obtained from the world wide web at: https://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx, CDC 2017. Last accessed on July 16, 2018 Ware, 2001, Interpreting SF-36 summary health measures: a response, Qual Life Res, 10, 405, 10.1023/A:1012588218728 Younossi, 1999, Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease, Gut, 45, 295, 10.1136/gut.45.2.295 Younossi, 2017, A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD, Liver Int, 37, 1209, 10.1111/liv.13391 Chawla, 2016, Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH), BMJ Open Gastroenterol, 3, 10.1136/bmjgast-2015-000069 National Institute of Mental Health. Depression. Obtained from the world wide web at: https://www.nimh.nih.gov/health/topics/depression/index.shtml. Weinstein, 2011, Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C, Psychosomatics, 52, 127, 10.1016/j.psym.2010.12.019 Golabi, 2016, Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL), Health Qual Life Outcomes, 9, 18, 10.1186/s12955-016-0420-z Dan, 2007, Health-related quality of life in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 26, 815, 10.1111/j.1365-2036.2007.03426.x Tapper, 2016, Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study, Hepatology, 63, 1184, 10.1002/hep.28416 Younossi, 2018, Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib, Liver Int, 10.1111/liv.13706 Ballestri, 2016, Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection—liver: the “musketeer” in the spotlight, Int J Mol Sci, 17, 355, 10.3390/ijms17030355 Joo, 2017, Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study, Hepatology, 65, 828, 10.1002/hep.28917 Cheng, 2013, Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up, PLoS One, 8 Younossi Z, Stepanova Z, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Non-alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality. American Association for the Study of Liver Annual Meeting 2018, San Francisco, CA. Younossi, 2018, The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options, J Hepatol, 69, 1365, 10.1016/j.jhep.2018.08.013 Ofosu, 2018, Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions, Ann Gastroenterol, 31, 288 Younossi, 2018, Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 68, 361, 10.1002/hep.29724 Golabi, 2017, Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Clin Liver Dis, 21, 739, 10.1016/j.cld.2017.06.010 Younossi, 2018, Patient-reported outcomes and the economic effects of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis – the value proposition, Hepatology, 10.1002/hep.30125 Romero-Gómez, 2017, Treatment of NAFLD with diet, physical activity and exercise, J Hepatol, 67, 829, 10.1016/j.jhep.2017.05.016 Kamal R, Cox C, Blumenkranz E, The Kaiser Family Foundation. What do we know about social determinants of health in the U.S. and comparable countries? Chart Collections Health & Wellbeing. Posted: November 21, 2017. Accessed on 10/23/2018 at https://www.healthsystemtracker.org/chart-collection/know-social-determinants-health-u-s-comparable-countries/#item-u-s-highest-environmental-burden-disease-compared-high-income-countries.